title: Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
authors.affiliation: Intensive Care Unit, Children's Hospital of the University of Tübingen, Tübingen, Germany. Maren.Tomaske@med.uni-tuebingen.de
authors.forename: Maren
authors.initials: M
authors.lastname: Tomaske
authors.forename: Oliver
authors.initials: O
authors.lastname: Amon
authors.forename: Axel
authors.initials: A
authors.lastname: Bosk
authors.forename: Rupert
authors.initials: R
authors.lastname: Handgretinger
authors.forename: E Marion
authors.initials: EM
authors.lastname: Schneider
authors.forename: Dietrich
authors.initials: D
authors.lastname: Niethammer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D002648:Child; D000077561:Daclizumab; D005047:Etoposide / Q000009:adverse effects; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D005047:Etoposide; D000077561:Daclizumab